HBMN:SWX
HBM Healthcare Investments AG
233,50 CHF
arrow_upward
+0,65%(+1,50) 1 D
30. apr., 14:46:07 GMT+2 · CHF
search
Alle symboler
1 D
5 D
1 M
6 M
I år
1 Å
5 Å
MAKS
| Symbol | Pris | Endring | Endring (%) |
|---|
insights_autoGenererer viktig statistikk for HBMN …
Åpne
231,50 CHF
Høy
235,00 CHF
Lav
228,00 CHF
Markedsverdi
1,57 mrd.
Snittvolum
6,47k
Volum
2,03k
Utbytte
3,21 %
Kvartalsvis utbytte
1,88 CHF
Første dato etter utbytte
2. juli 2025
P/E-forhold
6,50
52 u høy
245,50 CHF
52 u lav
157,40 CHF
EPS
35,93 CHF
Utestående aksjer
6,74 mill.
Nyhetssaker
Fra kilder på nettet
PR Newswire
·
for 18 minutter siden
Brand Engagement Network (NASDAQ: BNAI) Signs Definitive Agreement to Acquire Cataneo GmbH, a Global Media Infrastructure Leader, in a Debt-Free $19.5 Million Transaction
The Motley Fool
·
for 22 minutter siden
Meet the Unstoppable Vanguard ETF Beating the S&P 500, the Nasdaq-100, and the Dow Jones in 2026
GlobeNewswire
·
for 28 minutter siden
Check-Cap ($MBAI) Advances NASDAQ Listing for MBody AI Merger
Simply Wall Street
·
for 46 minutter siden
Foreign Capital And Regulators Reshape Outlook For Warner Bros. Discovery Merger
Profil
HBM Healthcare Investments is a publicly traded Swiss investment and venture capital firm focusing on emerging technologies in the global healthcare sector. Within healthcare their focus is predominantly in biotechnology, medical technology, diagnostics, therapeutics and digital health.
A 2022 article in Swiss daily Luzerner Zeitung profiled HBM and interviewed its CEO, and described the company’s investment strategy as focused on early-stage but post-seed round opportunities.
Founded in July 2001 as HBM Bioventures AG by former Roche Chief Financial Officer Henri B. Meier who was its first Chairperson of the Board. A Handelszeitung article from 2020 described Meier's goal when founding the company as to profit from the "thesis" that from the 2000s onwards "Big Pharma is doing less and less research and development itself and is instead acquiring promising biotech companies" In an analysis of how HBM was put together, Swiss magazine Finanz und Wirtschaft described how he was able to raise almost 500 million Swiss Francs for the company launch. HBM is based in Zug and managed by HBM Partners. HBM acquired rival Swiss VC International BM Biomedicine in 2005. Wikipedia
Om HBM Healthcare Investments AG
Administrerende direktør-
Ansatte-
Grunnlagt12. juli 2001
HovedkontorZug, Zug, Sveits
Sektor-
Nettstedhbmhealthcare.com
AI-innhold kan inneholde feil. Finn ut mer